# TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

> **NCT06664983** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 84 (estimated)

## Conditions studied

- Nasopharyngeal Cancinoma (NPC)

## Interventions

- **DRUG:** TPC chemotherapy
- **DRUG:** cadonilimab combined TPC chemotherapy

## Key facts

- **NCT ID:** NCT06664983
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-21
- **Primary completion:** 2025-10-21
- **Final completion:** 2026-10-21
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06664983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06664983, "TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06664983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*